{"entity":{"type":"insider","cik":"0001575852","url":"/insider/0001575852","json_url":"/insider/0001575852.json","name":"Lilly Ventures Fund I LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":7,"n_filings":7,"first":"2013-05-14","last":"2018-04-23","span_basis":"filed_date"},"name_variants":[{"name":"Lilly Ventures Fund I LLC","source":"filing","n_filings":7,"first_seen":"2013-05-14","last_seen":"2018-04-23"}],"transactions":[{"id":6725139,"accession":"0001209191-18-025824","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-025824","line_url":"/filing/0001209191-18-025824#line-2","is_derivative":false,"issuer_cik":"0001552293","issuer_name":"Surface Oncology, Inc.","issuer_ticker":"SURF","issuer_name_source":null,"issuer_url":"/issuer/0001552293","owner_cik":null,"owner_name":"Hall Steven Edward; LV Management Group, LLC; Lilly Ventures Fund I LLC; Torres S. Edward","owner_display_name":"Hall Steven Edward","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":266000.0,"shares_display":"266,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3990000.0,"total_display":"3,990,000.00","total_whole":"3,990,000","shares_owned_after":3447817.0,"shares_owned_after_display":"3,447,817","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-04-23","filed_date":"2018-04-23","scope":"insider"},{"id":5338814,"accession":"0000899243-17-018092","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-018092","line_url":"/filing/0000899243-17-018092#line-2","is_derivative":false,"issuer_cik":"0001420565","issuer_name":"AILERON THERAPEUTICS INC","issuer_ticker":"ALRN","issuer_name_source":null,"issuer_url":"/issuer/0001420565","owner_cik":null,"owner_name":"Hall Steven Edward; LV Management Group, LLC; Torres S. Edward; Lilly Ventures Fund I LLC","owner_display_name":"Hall Steven Edward","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3750000.0,"total_display":"3,750,000.00","total_whole":"3,750,000","shares_owned_after":1094987.0,"shares_owned_after_display":"1,094,987","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-07-05","filed_date":"2017-07-07","scope":"insider"},{"id":3294203,"accession":"0001209191-16-137314","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-16-137314","line_url":"/filing/0001209191-16-137314#line-4","is_derivative":false,"issuer_cik":"0001377121","issuer_name":"Protagonist Therapeutics, Inc","issuer_ticker":"PTGX","issuer_name_source":null,"issuer_url":"/issuer/0001377121","owner_cik":null,"owner_name":"Hall Steven Edward; Lilly Ventures Fund I LLC; LV Management Group, LLC; Torres S. Edward","owner_display_name":"Hall Steven Edward","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":583333.0,"shares_display":"583,333","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":6999996.0,"total_display":"6,999,996.00","total_whole":"6,999,996","shares_owned_after":2099482.0,"shares_owned_after_display":"2,099,482","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-08-16","filed_date":"2016-08-16","scope":"insider"},{"id":6769204,"accession":"0001209191-14-067900","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-14-067900","line_url":"/filing/0001209191-14-067900#line-3","is_derivative":false,"issuer_cik":"0000059478","issuer_name":"Coherus BioSciences, Inc.","issuer_ticker":"CHRS","issuer_name_source":null,"issuer_url":"/issuer/0000059478","owner_cik":null,"owner_name":"LILLY ELI & CO; Lilly Ventures Fund I LLC","owner_display_name":"LILLY ELI & CO","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":164963.0,"shares_display":"164,963","price_per_share":13.5,"price_display":"13.50","price_state":"stated","total_value":2227000.5,"total_display":"2,227,000.50","total_whole":"2,227,001","shares_owned_after":3042019.0,"shares_owned_after_display":"3,042,019","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-12","filed_date":"2014-11-12","scope":"insider"},{"id":6762887,"accession":"0001209191-14-027708","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-14-027708","line_url":"/filing/0001209191-14-027708#line-5","is_derivative":false,"issuer_cik":"0000059478","issuer_name":"Cerulean Pharma Inc.","issuer_ticker":"CERU","issuer_name_source":null,"issuer_url":"/issuer/0000059478","owner_cik":null,"owner_name":"Lilly Ventures Fund I LLC; LILLY ELI & CO","owner_display_name":"Lilly Ventures Fund I LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":733445.0,"shares_display":"733,445","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":5134115.0,"total_display":"5,134,115.00","total_whole":"5,134,115","shares_owned_after":2356227.0,"shares_owned_after_display":"2,356,227","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-04-15","filed_date":"2014-04-15","scope":"insider"},{"id":9196295,"accession":"0000059478-13-000082","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000059478-13-000082","line_url":"/filing/0000059478-13-000082#line-1","is_derivative":false,"issuer_cik":"0001552293","issuer_name":"Receptos, Inc.","issuer_ticker":"RCPT","issuer_name_source":null,"issuer_url":"/issuer/0001552293","owner_cik":null,"owner_name":"LILLY ELI & CO; Lilly Ventures Fund I LLC; Torres S. Edward","owner_display_name":"LILLY ELI & CO","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":142857.0,"shares_display":"142,857","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":1999998.0,"total_display":"1,999,998.00","total_whole":"1,999,998","shares_owned_after":2081210.0,"shares_owned_after_display":"2,081,210","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-05-14","filed_date":"2013-11-21","scope":"insider"},{"id":5280317,"accession":"0001104659-13-041519","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-13-041519","line_url":"/filing/0001104659-13-041519#line-3","is_derivative":false,"issuer_cik":"0001463729","issuer_name":"Receptos, Inc.","issuer_ticker":"RCPT","issuer_name_source":null,"issuer_url":"/issuer/0001463729","owner_cik":"0001575852","owner_name":"Lilly Ventures Fund I LLC","owner_display_name":"Lilly Ventures Fund I LLC","owner_url":"/insider/0001575852","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":142857.0,"shares_display":"142,857","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":1999998.0,"total_display":"1,999,998.00","total_whole":"1,999,998","shares_owned_after":2081210.0,"shares_owned_after_display":"2,081,210","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-14","filed_date":"2013-05-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":1,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":1},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001718108","name":"Surface Oncology, Inc.","url":"/issuer/0001718108","role":"Ten percent owner","n_filings":1,"first_seen":"2018-04-23","last_seen":"2018-04-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001420565","name":"AILERON THERAPEUTICS INC","url":"/issuer/0001420565","role":"Other","n_filings":1,"first_seen":"2017-07-07","last_seen":"2017-07-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001377121","name":"Protagonist Therapeutics, Inc","url":"/issuer/0001377121","role":"Ten percent owner","n_filings":1,"first_seen":"2016-08-16","last_seen":"2016-08-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001512762","name":"Coherus BioSciences, Inc.","url":"/issuer/0001512762","role":"Other","n_filings":1,"first_seen":"2014-11-12","last_seen":"2014-11-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001401914","name":"Cerulean Pharma Inc.","url":"/issuer/0001401914","role":"Ten percent owner","n_filings":1,"first_seen":"2014-04-15","last_seen":"2014-04-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001463729","name":"Receptos, Inc.","url":"/issuer/0001463729","role":"Ten percent owner","n_filings":2,"first_seen":"2013-05-14","last_seen":"2013-11-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001575852","retrieved_at":"2026-08-26T00:06:19+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}